Glenmark Pharmaceuticals has informed that, Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Adapalene Gel USP, 0.1% (OTC) in new pump packs. Glenmark’s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin®2 Gel, 0.1%. According to Nielsen® syndicated data for the latest 52-week period ending September 5, 2026, the Differin® Gel, 0.1% (OTC) market3 achieved annual sales of approximately $45.8 million*. The company has attached media release in this regard.
The above information is a part of company’s filings submitted to BSE.
